(Q46075268)

19 December 2017

title

Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders (English)

1 reference

19 December 2017

1 reference

Julia Kirchheiner

1

1 reference

19 December 2017

Cristina Rodriguez-Antona

series ordinal

2

1 reference

19 December 2017

publication date

1 January 2009

1 reference

19 December 2017

published in

CNS Drugs

1 reference

19 December 2017

volume

23

1 reference

19 December 2017

issue

3

1 reference

19 December 2017

page(s)

181-191

1 reference

19 December 2017

Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200923030-00001

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200923030-00001

Substantial rise in sparteine metabolic ratio during haloperidol treatment

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200923030-00001

Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.

21 January 2018

1 reference

12 December 2020

Severe liver injury after initiating therapy with atomoxetine in two children.

1 reference

12 December 2020

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study

1 reference

12 December 2020

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

1 reference

12 December 2020

CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD.

1 reference

12 December 2020

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

1 reference

12 December 2020

A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.

1 reference

12 December 2020

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

1 reference

12 December 2020

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

1 reference

12 December 2020

Clinical consequences of cytochrome P450 2C9 polymorphisms

1 reference

12 December 2020

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

1 reference

12 December 2020

Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting

1 reference

12 December 2020

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

1 reference

12 December 2020

Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.

1 reference

12 December 2020

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects

1 reference

12 December 2020

The dosing of atypical antipsychotics

1 reference

12 December 2020

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

1 reference

12 December 2020

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms

1 reference

12 December 2020

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

1 reference

12 December 2020

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms

1 reference

12 December 2020

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.

1 reference

12 December 2020

Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study

1 reference

12 December 2020

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

1 reference

12 December 2020

CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.

1 reference

12 December 2020

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences

1 reference

12 December 2020

Global burden of depressive disorders in the year 2000

1 reference

12 December 2020

Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes

1 reference

12 December 2020

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations

1 reference

12 December 2020

Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans

1 reference

12 December 2020

Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.

1 reference

12 December 2020

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

1 reference

12 December 2020

Combined overdose of atomoxetine and methylphenidate in a cytochrome P450 2D6 poor metabolizer

1 reference

12 December 2020

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype

1 reference

12 December 2020

Pharmacogenomics: translating functional genomics into rational therapeutics

1 reference

12 December 2020

Serum Concentrations and Side Effects in Psychiatric Patients During Risperidone Therapy

1 reference

12 December 2020

Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients

1 reference

12 December 2020

Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression

1 reference

12 December 2020

Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers

1 reference

12 December 2020

Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype

1 reference

12 December 2020

Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes

1 reference

12 December 2020

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

1 reference

12 December 2020

Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6

1 reference

12 December 2020

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity

1 reference

12 December 2020

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

1 reference

12 December 2020

Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

1 reference

12 December 2020

Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers

1 reference

12 December 2020

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

1 reference

12 December 2020

Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors

1 reference

12 December 2020

Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine

1 reference

12 December 2020

Pharmacokinetic and clinical significance of genetic variability in psychotropic drug metabolism

1 reference

12 December 2020

Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events.

1 reference

12 December 2020

Drug metabolism and atypical antipsychotics

1 reference

12 December 2020

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers

1 reference

12 December 2020

Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin

1 reference

12 December 2020

Venlafaxine serum levels and CYP2D6 genotype

1 reference

12 December 2020

Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

1 reference

12 December 2020

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

12 December 2020

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

1 reference

12 December 2020

Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).

1 reference

12 December 2020

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy

1 reference

12 December 2020

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

1 reference

12 December 2020

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

1 reference

12 December 2020

Non-linear fluvoxamine disposition

1 reference

12 December 2020

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

1 reference

12 December 2020

Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism

1 reference

12 December 2020

The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics

1 reference

12 December 2020

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation

1 reference

12 December 2020

The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

1 reference

12 December 2020

Routine pharmacogenetic testing in clinical practice: dream or reality?

1 reference

12 December 2020

10.2165/00023210-200923030-00001

Identifiers

DOI

1 reference

19 December 2017

Dimensions Publication ID

1015961040

0 references

1 reference

19 December 2017